Issue 68, 2015

A selective decoy–doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect

Abstract

A novel selective decoy oligodeoxynucleotide (dODN)–doxorubicin (DOX) complex is reported for cancer theranostics. It eliminates the use of a ligand or carrier for targeted delivery and disassembles into therapeutic dODN and DOX upon encountering over-activated STAT3 in cancer cells. Hence, in situ STAT3 probing and synergistic anti-cancer effect are attained at the same time.

Graphical abstract: A selective decoy–doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect

Supplementary files

Article information

Article type
Communication
Submitted
30 May 2015
Accepted
15 Jul 2015
First published
15 Jul 2015

Chem. Commun., 2015,51, 13309-13312

A selective decoy–doxorubicin complex for targeted co-delivery, STAT3 probing and synergistic anti-cancer effect

S. Wang, Y. Hou and L. Chen, Chem. Commun., 2015, 51, 13309 DOI: 10.1039/C5CC04435A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements